Exhibitors and other promotional activities

The exhibition is an integral part of the conference, providing delegates with the opportunity to converse directly with industry experts about development and research in cardiovascular products and innovation.

We are grateful to all our sponsors and exhibitors whose funding have contributed towards this independently produced meeting and programme. Sponsors and exhibitors have not had any editorial input or control over the agenda, scientific content development or choice of speakers, excluding dedicated industry symposia and masterclasses. 

See a full list of our exhibitors below:

Exhibitors for 2026

AstraZeneca is a global, science-led biopharmaceutical company, headquartered in the UK, that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals. For more information, please visit www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK.  

Stand number: 15

Website: https://www.astrazeneca.co.uk 

Bayer is a life sciences company and a global leader in healthcare and nutrition. Our products and services are designed to support efforts to overcome the major challenges presented by a growing and aging global population.

In the UK, Bayer is committed to supporting and addressing the needs of patients, the NHS and the clinical community through ongoing research and partnerships, working in a wide range of areas to maximise both clinical benefit and value delivered by new treatment approaches.

At Bayer, our mission is “Health for all, Hunger for none”. Through scientific innovations, we endeavour to shape the future of healthcare and nutrition. 

Website: https://pro.bayer.co.uk/

PP-BEY-GB-0241 April 2026

British Heart Foundation (BHF) powers groundbreaking scientific research into cardiovascular disease to save and improve lives. We fund over £100 million of lifesaving research into heart and circulatory diseases each year. We support you when you need us most. And we campaign for a healthier world.

Website: https://www.bhf.org.uk/

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve outcomes and enhance lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow.

Website: www.boehringer-ingelheim.com/uk (UK) or www.boehringer-ingelheim.com/ie (Ireland)

Boehringer Ingelheim has provided funding for BCS 2026 with no input into the conference agenda, speaker selection or presentation content beyond the Boehringer Ingelheim ‘Hot Topic’ session.

NP-GB-107205 April 2026

 

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. 

Website: bms.com/gb 

The British Inherited Cardiovascular Conditions Society (BICCS), formerly the AICC, is the national body representing healthcare professionals managing patients and their families with a range of genetic diseases, primarily affecting the heart.

These inherited cardiovascular conditions (ICCs) can affect:

  • the heart muscle (cardiomyopathies)
  • the heart’s rhythm and electrical system (ion channel disorders)
  • major blood vessels (aortopathies)
  • skeletal muscle as well as heart muscle (neuromuscular disorders)

These conditions can affect all ages, can be difficult to diagnose, can run in families and can affect quality of life and sometimes be associated with serious complications including sudden death. 

BICCS is a membership organisation that provides a forum in which healthcare professionals can meet, learn, educate, collaborate and ultimately work towards providing the very highest level of healthcare to our patients.

The BSH are the voice of Heart Failure – a UK wide community of health care professionals . We connect national expertise to improve heart failure. Our focus is on prevention and improving the impact on patients and society. We do this through education, lobbying, raising awareness and supporting research. 

We represent and support echocardiography professionals working at all levels and in all areas of the field. We provide our members with support to deliver the highest standard of care in echocardiography. We are a leading provider of education and accreditation and produce guidelines and resources to promote best practice.

Stand number: 25

Website: https://www.bsecho.org/

Cardiovascular Care Partnership (UK) is a patient-led charity working alongside clinicians to champion the voice of patients and carers in cardiovascular care. We collaborate on research, innovation, and service development to improve outcomes. Together, we can deliver more effective, person-centred cardiovascular services across the UK.

Stand number: 24

Website: https://www.ccpuk.org.uk/

Consent today is not fit for purpose. Even in advanced hospitals, it remains largely paper-based, leading to high medicolegal risk, poor patient understanding, and operational inefficiency. Over 50% of consent is completed on the day of surgery, contributing to delays and cancellations, while errors and omissions are common.

Concentric is the UK’s leading digital consent-to-treatment application, designed to transform how hospitals manage consent, shared decision-making, and medicolegal risk. Used by 40+ NHS Trusts, Concentric supports more than 2 million patients each year.

Clinicians use Concentric to create personalised, evidence-based consent using a library of 3,000+ procedure templates. Consent information is shared securely with patients ahead of treatment, enabling remote and two-stage consent pathways. The platform integrates seamlessly with existing clinical systems and workflows.

Concentric delivers system-wide benefits with an estimated ~50% reduction in medicolegal risk, improved operational efficiency, including fewer delays and cancellations, and enhanced patient understanding and shared decision-making.

Data4NHS maintains one of the largest healthcare related databases in the UK.  Registration is free and only available to NHS professionals with a valid NHS email address.  Register with us to have access to our resources including the Data4NHS national directory, recruitment opportunities, events and courses calendar, surveys and e-bulletin.   

Stand number: 19

Website: https://directory.data4nhs.com/

 

Dr.Noon CVD is a CE-marked, MHRA-accredited AI screening software using already-available fundus imaging that detects cardiovascular risk by analysing subtle changes in retinal blood vessels, with accuracy comparable to CT imaging.

Developed in collaboration with leading cardiologists and featured by the European Society of Cardiology (2024) and the American Heart Association (2025), it enables early detection of cardiovascular disease, even in patients with no symptoms. Unlike QRISK3 and other similar traditional tools relying on statistical methods, Dr.Noon reveals risk that often go unnoticed through vessel visualisation.

Its insights are backed by over 50 peer-reviewed publications, including The Lancet, JAMIA, and the Journal of Insurance Medicine, where it’s been described as a “game-changer” in preventative screening. 

Heart Research UK are a national charity dedicated to preventing and curing heart diseases.

For 60 years, we have invested in pioneering medical research to save as many lives as possible. We have delivered community-based health programmes designed to identify risk of heart conditions as soon as possible and empower people to take control of their own heart health.

We work with respected researchers, healthcare professionals and local communities across the UK to create lasting change for today and the future because everyone deserves the chance of a healthy heart.

 

Our Research

We fund high-quality research projects dedicated to finding even better ways to prevent, treat and cure heart diseases.

When we were founded in 1967, 80% of children with congenital heart disease died before their first birthday, and 70% of heart attacks were fatal. Today, 80% of those children survive to adulthood, and 70% of heart attack patients now survive.

By investing in innovative projects and supporting the next generation of cardiovascular researchers, we are accelerating progress toward better outcomes for patients.

From surgical advancements to new treatment approaches, our research funding helps turn scientific discovery into life-saving impact.

Our research projects are continually achieving breakthroughs and we won’t stop until there are no more deaths from heart diseases. 

 

Our Work in Communities

We deliver free community health checks across the UK so that we are able to come and see you in your community. 

Our heart health checks measure key risk factors such as blood pressure, cholesterol, BMI and lifestyle indicators, helping people understand their risk of heart disease and the steps they can take to reduce their risk.We provide practical tools, resources and guidance to support healthier everyday choices. We believe small changes can save lives.

Our Healthy Heart Grants empower and support community projects that promote healthier lifestyles and reduce the risk of heart diseases. We fund innovative ideas to help people live longer, happier lives, especially in at-risk communities.

Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition.

By delivering intelligent CAD analysis and management insights, Heartflow provides physicians with the clarity and confidence that their next clinical decision is the right one for each individual patient.

Heartflow FFRct is the only non-invasive, lesion-specific FFR prospectively validated against invasive gold standards and proven to improve patient outcomes. 

Heartflow has supported clinicians at over 1,800 institutions in managing more than 600,000 patients worldwide.

Hi-D Imaging: Precision Starts with Clarity

Hi-D Imaging represents a new standard in structural heart pre-procedural planning. Rather than overwhelming clinicians with raw data, Hi-D Imaging translates complex imaging into intuitive, clinically meaningful visuals, and enhancing confidence in even the most challenging anatomies. The result: faster interpretation, reduced variability, and a clearer path to decision-making.

4TAVR: One CT. One Click. One Report.

4TAVR, the flagship product of Hi-D Imaging, is an AI-powered planning platform that simplifies and standardizes the entire TAVR workflow. With just a single CT upload, the system automatically performs anatomical segmentation, anatomical measurements which leads to optimal valve sizing, evaluates key features with interactive 2D and 3D visuals, and generates a full structured report. Within minutes, clinicians receive a comprehensive and consistent analysis, replacing hours of manual work and reducing variability between operators.

Digital Twin Lab: One Stop Solution for Testing

Structural heart diseases are not just anatomical conditions, they are fundamentally flow-driven disorders. Whether in valve disease, congenital defects, or aortic pathologies, hemodynamics determine disease progression, treatment response, and device performance. Yet today, our ability to predict patient-specific flow remains limited, with most decisions still relying on static imaging and simplified assumptions.

Why does this matter now? Because the field is at a turning point. With the rapid expansion of transcatheter therapies and increasingly complex patient populations, the need to predict outcomes before intervention is becoming critical for improving patient selection, increasing procedural confidence, and de-risking innovation.

This is where Hi-D Imaging’s physically enhanced digital twin technology introduces a new paradigm. Starting from routine CT or MRI data, patient-specific anatomies are translated into high-fidelity models and combined with advanced in-vitro flow measurements. This approach reconstructs four-dimensional hemodynamics, capturing both instantaneous and phase-averaged flow fields. Unlike purely computational approaches, these digital twins are grounded in measured physics, providing validated insights into flow patterns, pressure gradients, vortex formation, and device–flow interactions.

The potential is substantial. For virtual clinical trials, digital twins enable simulation of therapies across diverse patient cohorts, supporting better patient selection, optimized trial design, and increased confidence in outcomes before first-in-human studies. For medtech R&D, they offer realistic and reproducible environments to accelerate design, validate simulations, and reduce uncertainty. Importantly, this approach can also contribute to reducing reliance on animal studies by replicating physiological conditions in a controlled, patient-specific setting.

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Website: www.msd-uk.com 

MSD has provided funding for BCS 2026 but has had no further input into any other aspect of this conference, aside from an MSD non-promotional medical exhibition stand.

Date of Prep: April 2026 | GB-NON-12937

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

In the UK, we champion health and lives through pioneering NHS partnerships, innovative collaborations and a clear focus on the greatest healthcare challenges we all face. We are where science meets hope.

Website: https://www.novartis.com/uk-en/ 

Novartis Pharmaceuticals UK Ltd. has provided funding only for the BCS 2026 as part of a sponsorship. Novartis has had no input into the content, organisation, conduct or outputs relating to the Event.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes.

Pharma Nord is one of Europe’s leading manufacturers of dietary supplements and preventative nutrition. We believe in the science of supplements; we support cutting-edge research in UK and abroad. Our products have been used in more than 300 clinical trials across the world, offering extensive, documented evidence of their safety, bioavailability and effectiveness. Our approach has attracted advocates including cardiologists, health writers and pharmacists.

Website: https://www.pharmanord.co.uk/ 

The Primary Care Cardiovascular Society (PCCS) is a multi-disciplinary society reflecting the ideas and opinions of primary care healthcare professionals throughout the UK involved in managing cardiovascular patient care and improving cardiovascular health.

Our range of conferences throughout the year provide a stimulating forum for hearing the latest advances in cardiovascular medicine, sharing best practice and networking with colleagues and peers. 


Recordati Pharmaceuticals Limited is part of Recordati S.p.A., a global pharmaceutical group with a 100-year heritage, dedicated to delivering value-added medicines that help people unlock the full potential of life. In the UK we focus on the commercialisation and distribution of therapies across key areas such as urology, uro-oncology and cardiovascular health, supporting patients and healthcare professionals through its established primary and specialty care portfolio.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.

Website: https://www.sanofi.co.uk/en

Sky Labs helps chronic disease patients enjoy a life of happiness without limitations, even outside the hospital. As an AI healthcare platform company leading global innovation, we prevent diseases and design a healthier future through precise daily monitoring.

Spacelabs Healthcare is solely dedicated to developing patient monitoring and diagnostic cardiology technologies and services that empower providers to deliver exceptional patient care.

Legacy of Innovation. Future of Possibility

We were there. In 1965, our groundbreaking telemetry became the first test of remote monitoring as it tracked the health of astronauts circling the globe. This auspicious beginning set Spacelabs Healthcare on a mission to advance care here on Earth and it led us to the moniker we proudly wear today.

But our name is not simply based on where we’ve been. It’s a reflection of the opportunities before us. We see limitless possibilities to advance patient care. New frontiers to explore. Pioneering advancements to chart.

We are inspired to solve the problems healthcare providers face in their quest to provide exceptional care.

Changing what’s possible for women in cardiology

The British Cardiovascular Society is committed to increasing the number of women training in cardiology and to support women cardiologists already working within the specialty.

We want to champion changes, address gender inequality in working practice and create a community of female cardiology trainees and consultants across the UK. The aims of the BCS Women in Cardiology team are to:

  • Engage – To develop new initiatives to attract female doctors to cardiology in the UK
  • Collaborate – To work with other cardiology societies to identify and address reasons for gender inequality
  • Support – To champion changes in working practice which promote equity for male and female cardiologists and trainees
  • Inform – To provide contemporary educational resources and support re issues relevant to women in cardiology
  • Network – To create a community of female cardiology trainees/consultants across the UK

The UK CARDIO-IMID Partnership is the first national network of inter-disciplinary rheumatology and cardiovascular clinicians, clinician scientists and basic scientists that wish to address the unmet needs of people with immune-mediated inflammatory diseases (IMIDs) and cardiovascular involvement, and thereby improve outcomes of people with IMID-CVD and the wider population.

Our mission is to transform the management of cardiovascular involvement of people with IMIDs through better understanding of inflammation science of cardiovascular disease, enhanced diagnostics and monitoring and precision therapeutics. This will be achieved by establishing a world class patient-centred, dynamic and sustainable, collaborative UK infrastructure in cardio-rheumatology to conduct scalable experimental medicine research and targeted therapeutic trials.

We initially developed a UK network of cardiovascular and rheumatology clinicians and researchers from 30 centres across the UK with the support of the NIHR-British Heart Foundation Cardiovascular Partnership. With Medical Research Council and British Heart Foundation (BHF) co-funding awarded in 2023, we have established the UK CARDIO-IMID Partnership.

Working across this national network that reaches all devolved nations, the UK CARDIO-IMID Partnership is working to strengthen collaborations to support training and education in cardio-rheumatology, sharing of best practice and development and delivery of high-quality biomedical research studies.

We are an inclusive working group and welcome investigators with ideas for collaborative education and research efforts at the intersection of inflammatory and cardiovascular diseases.

 

 

 

We have recently launched our educational platform, the UK CARDIO-IMID Hub hosted by MEDShr, which provides bespoke cardio-rheumatology training delivered by world-leading experts from both disciplines. The UK CARDIO-IMID Hub is free-to-access for all healthcare professionals across the UK and Republic of Ireland and we warmly invite you to sign-up using the link below or the QR code in our ‘Resources’ section.

https://en.medshr.net/groups/uk-cardio-imid

 

ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. 

Website: www.zoll.com

Exhibition Hall

Book your stand and symposia

If you haven’t already, it’s time to book your stand and symposia at the UK’s leading and largest cardiovascular event. BCS2025 offers a variety of opportunities to showcase your company, products and initiatives to an audience of over 2,000 healthcare professionals in the field of cardiology.

The conference, returns to Manchester Central and predominantly attracts consultant and trainee cardiologists, but delegates also include nurses, cardiac physiologists, scientists, and primary care staff.

The event attracts high profile speakers from the UK and overseas, including the leadership of the European Society of Cardiology, American College of Cardiology and the Cardiological Society of India, and provides education across the cardiology curriculum to fulfil the needs of trainees and the revalidation requirements of consultants.

Key elements of the conference include the BCS Education Zone, offering tailored, one-to-one, hands-on training for simulator and imaging, masterclasses, moderated posters and the ever popular ‘Hot Topics’ zones. All are situated in the Education Hall alongside our exhibitors providing a constant hub of activity and increased footfall.